Neuropeptide Y Induces Hematopoietic Stem/Progenitor Cell Mobilization by Regulating Matrix Metalloproteinase‐9 Activity Through Y1 Receptor in Osteoblasts. (18th May 2016)

• Record Type: Journal Article
• Authors: Park, Min Hee; Lee, Jong Kil; Kim, Namoh; Min, Woo‐Kie; Lee, Jeong Eun; Kim, Kyoung‐Tae; Akiyama, Haruhiko; Herzog, Herbert; Schuchman, Edward H.; Jin, Hee Kyung; Bae, Jae‐sung
• Is Part Of: Stem cells. Volume 34:Number 8(2016:Aug.)
• Page Start: 2145
• Page End: 2156
• Publication Date: 2016-05-18
• Subjects: Neuropeptide Y -- Bone marrow environment -- Hematopoietic stem/progenitor cell -- Mobilization -- Bone loss; Cloning -- Periodicals; Clone cells -- Periodicals; Stem cells -- Periodicals; Cell Differentiation -- Periodicals; Cell Division -- Periodicals; Clone Cells -- Periodicals; Hematopoietic Stem Cells -- Periodicals; Stem Cells -- Periodicals; 571.84
• DOI: 10.1002/stem.2383
• Languages: English
• ISSNs: 1066-5099

Abstract

Abstract: Hematopoietic stem/progenitor cell (HSPC) mobilization is an essential homeostatic process regulated by the interaction of cellular and molecular components in bone marrow niches. It has been shown by others that neurotransmitters released from the sympathetic nervous system regulate HSPC egress from bone marrow to peripheral blood. In this study, we investigate the functional role of neuropeptide Y (NPY) on this process. NPY deficient mice had significantly impaired HSPC mobilization due to increased expression of HSPC maintenance factors by reduction of matrix metalloproteinase‐9 (MMP‐9) activity in bone marrow. Pharmacological or endogenous elevation of NPY led to decrease of HSPC maintenance factors expression by activating MMP‐9 in osteoblasts, resulting in HSPC mobilization. Mice in which the Y1 receptor was deleted in osteoblasts did not exhibit HSPC mobilization by NPY. Furthermore, NPY treatment in ovariectomized mice caused reduction of bone loss due to HSPC mobilization. These results suggest a new role of NPY on HSPC mobilization, as well as the potential therapeutic application of this neuropeptide for stem cell‐based therapy. Stem Cells 2016;34:2145–2156